Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEZI-KD
2025-521090-14-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2026
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mezigdomide in multiple myeloma (MM), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Progression-free survival (PFS). Planned start Apr 2026; status: authorised.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2025-521090-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521090-14-00.